Login to Your Account


Hua Medicine tests glucokinase activator in Chinese diabetics

By Shannon Ellis
Staff Writer

Wednesday, March 26, 2014

SHANGHAI – Hua Medicine Ltd. has commenced a phase Ib trial for HMS5552, a glucokinase activator (GKA), in early stage type 2 diabetes patients in a multicenter, multidose study in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription